BioVie Inc近日宣布,其针对早期帕金森病(Parkinson's Disease)的候选药物Bezisterim,在名为Sunrise-Pd的2期临床试验中,取得了关键性顶线研究成果。这一消息引发了市场与医学界的广泛关注,为神经退行性疾病治疗领域注入了新的期待。
BioVie Inc近日宣布,其针对早期帕金森病(Parkinson's Disease)的候选药物Bezisterim,在名为Sunrise-Pd的2期临床试验中,取得了关键性顶线研究成果。这一消息引发了市场与医学界的广泛关注,为神经退行性疾病治疗领域注入了新的期待。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.